Testing cognitive normal for Alzheimer's disease prediction

J Neurochem. 2025 Jan;169(1):e16272. doi: 10.1111/jnc.16272.

Abstract

One standing challenge for Alzheimer's disease (AD) research is early diagnosis, which provides a time window for early intervention. Sharmin et al recently reported a positive association between plasma ptau181 and plasma metabolites, medium- and long-chain acylcarnitines (ACs) in both cognitively normal (CN) Aβ- and CN Aβ+ older adults, suggesting a link between initial Aβ pathology and acylcarnitine-mediated energy metabolism pathways. Consistently, ACs could classify PET-Aβ status in elderly individuals. This study has provided further clues for early biomarker searching for AD, linking metabolic pathways with AD pathogenesis.

Keywords: Alzheimer's disease; Aβ pathology; medium‐ and long‐chain acylcarnitines; plasma ptau181.

Publication types

  • Editorial

MeSH terms

  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / metabolism
  • Amyloid beta-Peptides / blood
  • Amyloid beta-Peptides / metabolism
  • Biomarkers / blood
  • Carnitine / analogs & derivatives
  • Carnitine / blood
  • Carnitine / metabolism
  • Cognition / physiology
  • Early Diagnosis
  • Humans
  • Positron-Emission Tomography
  • Predictive Value of Tests

Substances

  • acylcarnitine
  • Amyloid beta-Peptides
  • Biomarkers
  • Carnitine